BioCentury
ARTICLE | Clinical News

BioSante begins Phase II

May 16, 2001 7:00 AM UTC

BioSante (BTPH; CDNX:BAI) began a Phase II trial of its LibiGel transdermal testosterone gel to treat female sexual dysfunction (FSD) from low testosterone levels following menopause. The study will e...